These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

802 related items for PubMed ID: 15113612

  • 1. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.
    Agrawal S, Singh I, Kaur KJ, Bhade SR, Kaul CL, Panchagnula R.
    Int J Pharm; 2004 May 19; 276(1-2):41-9. PubMed ID: 15113612
    [Abstract] [Full Text] [Related]

  • 2. Oral bioavailability of rifampicin, isoniazid, ethambutol, and pyrazinamide in a 4-drug fixed-dose combination compared with the separate formulations in healthy Chinese male volunteers.
    Xu J, Jin H, Zhu H, Zheng M, Wang B, Liu C, Chen M, Zhou L, Zhao W, Fu L, Lu Y.
    Clin Ther; 2013 Feb 19; 35(2):161-8. PubMed ID: 23410999
    [Abstract] [Full Text] [Related]

  • 3. The pharmacokinetic factors and bioavailability of rifampicin, isoniazid and pyrazinamid fixed in one dose capsule.
    Zwolska Z, Augustynowicz-Kopeć E, Niemirowska-Mikulska H.
    Acta Pol Pharm; 2002 Feb 19; 59(6):448-52. PubMed ID: 12669769
    [Abstract] [Full Text] [Related]

  • 4. Assessment of bioequivalence of rifampicin, isoniazid and pyrazinamide in a four drug fixed dose combination with separate formulations at the same dose levels.
    Agrawal S, Kaur KJ, Singh I, Bhade SR, Kaul CL, Panchagnula R.
    Int J Pharm; 2002 Feb 21; 233(1-2):169-77. PubMed ID: 11897421
    [Abstract] [Full Text] [Related]

  • 5. Bioequivalence assessment of rifampicin, isoniazid and pyrazinamide in a fixed dose combination of rifampicin, isoniazid, pyrazinamide and ethambutol vs. separate formulations.
    Agrawal S, Singh I, Kaur KJ, Bhade SR, Kaul CL, Panchagnula R.
    Int J Clin Pharmacol Ther; 2002 Oct 21; 40(10):474-81. PubMed ID: 12395981
    [Abstract] [Full Text] [Related]

  • 6. Bioequivalence of isoniazid in a two drug fixed dose combination and in a single drug dosage form.
    Agrawal S, Kaul CL, Panchagnula R.
    Pharmazie; 2001 Aug 21; 56(8):636-9. PubMed ID: 11534341
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of bioequivalence of isoniazid and pyrazinamide in three and four drugs fixed dose combinations using WHO simplified protocol.
    Panchagnula R, Sancheti P, Rungta S, Agrawal S, Kaul CL.
    Pharmacol Res; 2003 Oct 21; 48(4):383-7. PubMed ID: 12902209
    [Abstract] [Full Text] [Related]

  • 8. Bioequivalence study of rifampicin in fixed-dose combination of rifampicin and isoniazid vs. separate formulations.
    Panchagnula R, Singh I, Kaur KJ, Kaul CL.
    Methods Find Exp Clin Pharmacol; 1999 Nov 21; 21(9):625-8. PubMed ID: 10669909
    [Abstract] [Full Text] [Related]

  • 9. Bioavailability of rifampicin, isoniazid and pyrazinamide in a triple drug formulation: comparison of plasma and urine kinetics.
    Gurumurthy P, Ramachandran G, Vijayalakshmi S, Kumar AK, Venkatesan P, Chandrasekaran V, Vjayasekaran V, Kumaraswami V, Prabhakar R.
    Int J Tuberc Lung Dis; 1999 Feb 21; 3(2):119-25. PubMed ID: 10091876
    [Abstract] [Full Text] [Related]

  • 10. Bioequivalence of fixed-dose combination Myrin®-P Forte and reference drugs in loose combination.
    Wang HF, Wang R, O'Gorman M, Crownover P, Naqvi A, Jafri I.
    Int J Tuberc Lung Dis; 2013 Dec 21; 17(12):1596-601. PubMed ID: 24200275
    [Abstract] [Full Text] [Related]

  • 11. The potential use of urinary excretion data for assessing the relative bioavailability of rifampicin in fixed dose combination anti-tuberculosis formulations.
    Pillai G, Ellard GA, Smith PJ, Fourie PB.
    Int J Tuberc Lung Dis; 2001 Aug 21; 5(8):691-5. PubMed ID: 11495257
    [Abstract] [Full Text] [Related]

  • 12. Modification to improve efficiency of sampling schedules for BA/BE testing of FDC anti-tuberculosis drugs.
    Gabriels GA, McIlleron H, Smith PJ, Folb PI, Fourie PB.
    Int J Tuberc Lung Dis; 2007 Feb 21; 11(2):181-8. PubMed ID: 17263289
    [Abstract] [Full Text] [Related]

  • 13. Comparative bioavailability of rifampicin and isoniazid in fixed-dose combinations and single-drug formulations.
    Hao LH, Guo SC, Liu CC, Zhu H, Wang B, Fu L, Chen MT, Zhou L, Chi JY, Yang W, Nie WJ, Lu Y.
    Int J Tuberc Lung Dis; 2014 Dec 21; 18(12):1505-12. PubMed ID: 25517820
    [Abstract] [Full Text] [Related]

  • 14. Recent bioequivalence studies on fixed-dose combination anti-tuberculosis drug formulations available on the global market.
    Pillai G, Fourie PB, Padayatchi N, Onyebujoh PC, McIlleron H, Smith PJ, Gabriels G.
    Int J Tuberc Lung Dis; 1999 Nov 21; 3(11 Suppl 3):S309-16; discussion S317-21. PubMed ID: 10593710
    [Abstract] [Full Text] [Related]

  • 15. Bioavailability of rifampicin, isoniazid and pyrazinamide from fixed-dose combination capsules.
    Zwolska Z, Niemirowska-Mikulska H, Augustynowicz-Kopec E, Walkiewicz R, Stambrowska H, Safianowska A, Grubek-Jaworska H.
    Int J Tuberc Lung Dis; 1998 Oct 21; 2(10):824-30. PubMed ID: 9783530
    [Abstract] [Full Text] [Related]

  • 16. Comparative bioequivalence study of rifampicin and isoniazid combinations in healthy volunteers.
    Padgaonkar KA, Revankar SN, Bhatt AD, Vaz JA, Desai ND, D'Sa S, Shah V, Gandewar K.
    Int J Tuberc Lung Dis; 1999 Jul 21; 3(7):627-31. PubMed ID: 10423226
    [Abstract] [Full Text] [Related]

  • 17. Comparative bioavailability of isoniazid, rifampin, and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy. I. Single-dose study.
    Acocella G, Nonis A, Gialdroni-Grassi G, Grassi C.
    Am Rev Respir Dis; 1988 Oct 21; 138(4):882-5. PubMed ID: 3202464
    [Abstract] [Full Text] [Related]

  • 18. Relative bioavailability of isoniazid in a fixed-dose combination product in healthy Mexican subjects.
    Milán-Segovia RC, Vigna-Pérez M, Romero-Méndez MC, Medellín-Garibay SE, Vargas-Morales JM, Magaña-Aquino M, Romano-Moreno S.
    Int J Tuberc Lung Dis; 2014 Jan 21; 18(1):49-54. PubMed ID: 24365552
    [Abstract] [Full Text] [Related]

  • 19. Relative bioavailability of rifampicin in a three-drug fixed-dose combination formulation.
    Milán-Segovia RC, Domínguez-Ramírez AM, Jung-Cook H, Magaña-Aquino M, Romero-Méndez MC, Medellín-Garibay SE, Vigna-Pérez M, Romano-Moreno S.
    Int J Tuberc Lung Dis; 2010 Nov 21; 14(11):1454-60. PubMed ID: 20937187
    [Abstract] [Full Text] [Related]

  • 20. Bioavailability of isoniazid, rifampicin and pyrazinamide (in free combination or fixed-triple formulation) in intermittent antituberculous chemotherapy.
    Acocella G, Luisetti M, Grassi GG, Peona V, Pozzi E, Grassi C.
    Monaldi Arch Chest Dis; 1993 Nov 21; 48(3):205-9. PubMed ID: 8369784
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.